|
55
|
JW Pharmaceutical to Present Preclinical Results for Rare Pediatric Brain Disease Drug Candidate at World Orphan Drug Congress USA |
2026-05-14 |
|
54
|
JW Pharmaceutical Completes Last Patient Dosing in Phase 3 Clinical Trial for Gout Treatment 'Epaminurad' |
2026-04-27 |
|
53
|
JW Pharmaceutical Signs Exclusive In-Licensing Agreement with Gan & Lee for 'Bi-Weekly' GLP-1 Obesity Drug |
2026-04-09 |
|
52
|
JW Pharmaceutical Receives Phase 1 IND Approval for Hair Loss Treatment Candidate 'JW0061' |
2026-02-13 |
|
51
|
JW Pharmaceutical Secures U.S. Patent for First-in-Class Hair Loss Treatment Candidate 'JW0061' |
2026-01-19 |
|
50
|
JW Pharmaceutical’s AI-Driven Innovative Metabolic Disease Drug Candidate Selected for National Drug Development Project |
2025-12-08 |
|
49
|
JW Pharmaceutical Secures U.S. Method-of-Use Patent for Gout Treatment 'Epaminurad' |
2025-12-03 |
|
48
|
STAT6-Targeted Eosinophilic Esophagitis Treatment Selected for National Drug Development Project |
2025-06-30 |
|
47
|
C&C Research Laboratories Presents Preclinical Data for Novel AML Therapy Candidate at AACR 2025 |
2025-04-29 |
|
46
|
JW Pharmaceutical Collaborates with U.S.-Based Tempus AI to Develop Anti-Cancer Drugs Using Clinical Data and Organoids |
2024-10-29 |